Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer

Yeh,Chia-Ming; Shay,Jacqueline; Zeng,Ting-Chuan; Chou,Jian-Liang; Huang,Tim  H.-M.; Lai,Hung-Cheng; Chan,Michael  W.Y.

doi:10.3892/ijo.2014.2627

Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer

Authors:
- Chia-Ming Yeh
- Jacqueline Shay
- Ting-Chuan Zeng
- Jian-Liang Chou
- Tim H.-M. Huang
- Hung-Cheng Lai
- Michael W.Y. Chan
View Affiliations

Affiliations: Department of Life Science and, National Chung Cheng University, Chia-Yi, Taiwan, R.O.C., Department of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center, San Antonio, TX, USA, Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, R.O.C.
Published online on: August 29, 2014 https://doi.org/10.3892/ijo.2014.2627
Pages: 2101-2107

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the fifth leading cause of cancer death and the most deadly gynecological malignancy in women. Epigenetic modifications play an important role in regulating gene transcription. Specifically, aberrant promoter hypermethylation has been implicated as a hallmark of cancer. In order to identify genes that are differentially methylated in ovarian cancer, we performed meDIP-chip in various ovarian cancer cell lines using Agilent 244K CpG island microarray. One of the targets, ARNTL which is a core component of the circadian clock is methylated in a sub-set of ovarian cancer cell lines. Combined bisulfite restriction analysis (COBRA) confirmed the results of the microarray. Additional analysis using ChIP-PCR revealed that promoter of ARNTL is enriched with the repressive histone mark H3K27me3 in CP70 and MCP2 ovarian cancer cells. Treatment with the EZH2 inhibitor (GSK126) significantly restored ARNTL expression in these cells (CP70 and MCP2). Further functional analysis demonstrated that overexpression of ARNTL inhibited cell growth and enhanced chemosensitivity of cisplatin in ovarian cancer cells. Finally, overexpression of ARNTL restored the rhythmic activity of c-MYC in ovarian cancer cells. These results suggested that ARNTL may be a tumor suppressor and is epigenetically silenced in ovarian cancer.

View Figures

View References

1	Sellix MT and Menaker M: Circadian clocks in the ovary. Trends Endocrinol Metab. 21:628–636. 2010. View Article : Google Scholar : PubMed/NCBI
2	Harrington ME: Exercise strengthens circadian clocks. J Physiol. 590:59292012. View Article : Google Scholar : PubMed/NCBI
3	Green CB and Menaker M: Circadian rhythms. Clocks on the brain. Science. 301:319–320. 2003. View Article : Google Scholar : PubMed/NCBI
4	Falcon J: Cellular circadian clocks in the pineal. Prog Neurobiol. 58:121–162. 1999. View Article : Google Scholar
5	Stevens RG and Rea MS: Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control. 12:279–287. 2001. View Article : Google Scholar : PubMed/NCBI
6	Hansen J: Risk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark. Cancer Causes Control. 17:531–537. 2006. View Article : Google Scholar : PubMed/NCBI
7	Schernhammer ES, Laden F, Speizer FE, et al: Night-shift work and risk of colorectal cancer in the nurses’ health study. J Natl Cancer Inst. 95:825–828. 2003.
8	Canaple L, Kakizawa T and Laudet V: The days and nights of cancer cells. Cancer Res. 63:7545–7552. 2003.PubMed/NCBI
9	Levin RD, Daehler MA, Grutsch JF, et al: Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer. 93:1202–1208. 2005. View Article : Google Scholar : PubMed/NCBI
10	Gery S and Koeffler HP: Circadian rhythms and cancer. Cell Cycle. 9:1097–1103. 2010. View Article : Google Scholar : PubMed/NCBI
11	Leonardi GC, Rapisarda V, Marconi A, et al: Correlation of the risk of breast cancer and disruption of the circadian rhythm (Review). Oncol Rep. 28:418–428. 2012.PubMed/NCBI
12	Yu EA and Weaver DR: Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging (Albany, NY). 3:479–493. 2011.PubMed/NCBI
13	Rana S and Mahmood S: Circadian rhythm and its role in malignancy. J Circadian Rhythms. 8:32010. View Article : Google Scholar : PubMed/NCBI
14	Paschos GK and FitzGerald GA: Circadian clocks and vascular function. Circ Res. 106:833–841. 2010. View Article : Google Scholar : PubMed/NCBI
15	Takahashi JS, Hong HK, Ko CH and McDearmon EL: The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet. 9:764–775. 2008. View Article : Google Scholar : PubMed/NCBI
16	Hunt T and Sassone-Corsi P: Riding tandem: circadian clocks and the cell cycle. Cell. 129:461–464. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ripperger JA and Schibler U: Rhythmic CLOCK-BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions. Nat Genet. 38:369–374. 2006. View Article : Google Scholar : PubMed/NCBI
18	Hsu CM, Lin SF, Lu CT, Lin PM and Yang MY: Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumour Biol. 33:149–155. 2012. View Article : Google Scholar : PubMed/NCBI
19	Tokunaga H, Takebayashi Y, Utsunomiya H, et al: Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand. 87:1060–1070. 2008. View Article : Google Scholar : PubMed/NCBI
20	Yang MY, Chang JG, Lin PM, et al: Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci. 97:1298–1307. 2006. View Article : Google Scholar : PubMed/NCBI
21	Baylin SB and Jones PA: A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
22	Seisenberger S, Peat JR and Reik W: Conceptual links between DNA methylation reprogramming in the early embryo and primordial germ cells. Curr Opin Cell Biol. 25:281–288. 2013. View Article : Google Scholar : PubMed/NCBI
23	Caslini C, Capo-chichi CD, Roland IH, Nicolas E, Yeung AT and Xu XX: Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene. 25:5446–5461. 2006. View Article : Google Scholar : PubMed/NCBI
24	Yu Y, Fujii S, Yuan J, et al: Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann NY Acad Sci. 983:268–277. 2003. View Article : Google Scholar : PubMed/NCBI
25	Chan MW, Wei SH, Wen P, et al: Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res. 11:7376–7383. 2005. View Article : Google Scholar : PubMed/NCBI
26	Chan MW, Huang YW, Hartman-Frey C, et al: Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia. 10:908–919. 2008.PubMed/NCBI
27	Chou JL, Su HY, Chen LY, et al: Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest. 90:414–425. 2010. View Article : Google Scholar : PubMed/NCBI
28	Yeh KT, Chen TH, Yang HW, et al: Aberrant TGFbeta/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer. Epigenetics. 6:727–739. 2011. View Article : Google Scholar : PubMed/NCBI
29	Su HY, Lai HC, Lin YW, Chou YC, Liu CY and Yu MH: An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer. 124:387–393. 2009. View Article : Google Scholar : PubMed/NCBI
30	Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY and Chang DD: Periostin secreted by epithelial ovarian carcinoma is a ligand for αVβ3 and αVβ5 integrins and promotes cell motility. Cancer Res. 62:5358–5364. 2002.PubMed/NCBI
31	McCabe MT, Ott HM, Ganji G, et al: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 492:108–112. 2012. View Article : Google Scholar : PubMed/NCBI
32	Fu LN, Pelicano H, Liu JS, Huang P and Lee CC: The circadian gene period2 plays an important role in tumor suppression and DNA-damage response in vivo. Cell. 111:1055. 2002. View Article : Google Scholar : PubMed/NCBI
33	Fu L and Lee CC: The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 3:350–361. 2003. View Article : Google Scholar : PubMed/NCBI
34	Hoffman AE, Zheng T, Ba Y and Zhu Y: The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res. 6:1461–1468. 2008.
35	Gery S, Komatsu N, Kawamata N, et al: Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res. 13:1399–1404. 2007. View Article : Google Scholar : PubMed/NCBI
36	Taniguchi H, Fernandez AF, Setien F, et al: Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res. 69:8447–8454. 2009. View Article : Google Scholar : PubMed/NCBI
37	Shih MC, Yeh KT, Tang KP, Chen JC and Chang JG: Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. Mol Carcinog. 45:732–740. 2006. View Article : Google Scholar : PubMed/NCBI
38	Mullenders J, Fabius AW, Madiredjo M, Bernards R and Beijersbergen RL: A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PloS one. 4:e47982009. View Article : Google Scholar : PubMed/NCBI
39	Jung CH, Kim EM, Park JK, et al: Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncol Rep. 29:2109–2113. 2013.PubMed/NCBI
40	Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
41	Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
42	Vire E, Brenner C, Deplus R, et al: The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI